Protia Inc. (KOSDAQ:303360)

South Korea · Delayed Price · Currency is KRW

5,930.00

-100.00 (-1.66%)

At close: Oct 2, 2026

Market Cap	76.38B +25.8%
Revenue (ttm)	17.75B +42.8%
Net Income	5.50B +92.2%
EPS	425.54 +90.8%
Shares Out	12.88M
PE Ratio	13.94
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,583
Open	6,170.00
Previous Close	6,030.00
Day's Range	5,900.00 - 6,170.00
52-Week Range	3,680.00 - 6,890.00
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Protia

Protia Inc. manufactures and sells in vitro diagnostic medical devices in South Korea. It offers allergy, animal diagnosis, autoimmune, antibiotic susceptibility, POCT, cancer, and related instrument products, as well as protein analysis, LC-MS/MS, characterization analysis, and custom protein services. The company was formerly known as ProteomeTech Inc. and changed its name to Protia Inc. in November 2023. Protia Inc. was founded in 2000 and is headquartered in Seoul, South Korea. [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2000

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 303360

Full Company Profile

Financial Performance

In 2025, Protia's revenue was 15.12 billion, an increase of 43.80% compared to the previous year's 10.51 billion. Earnings were 4.47 billion, an increase of 83.09%.

Financial Statements